Keywords: Zhejiang Hisun, Celsion, ThermoDox, Greater China option agreement, Patent applications

Zhejiang Hisun Pharma pulls out of ThermoDox deal with Celsion

Article | 07 February 2013

Print This

US cancer drug developer Celsion Corp (Nasdaq: CLSN) says that Zhejiang Hisun Pharmaceutical (SSE: 600267) does not plan to pursue the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in